NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Forecast, Price & News

$2.38

-0.06 (-2.46%)

(As of 09/22/2023 ET)

Compare

Today's Range: $2.34
▼
$2.51
50-Day Range: $2.04
▼
$2.54
52-Week Range: $0.95
▼
$3.57

Volume: 69,253 shs
Average Volume: 112,988 shs
Market Capitalization: $96.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.67

Spruce Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 222.1% Upside
$7.67 Price Target
Short Interest: Healthy
0.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.40) to ($1.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

203rd out of 969 stocks

Pharmaceutical Preparations Industry

76th out of 440 stocks

4.5

Analyst's Opinion

Consensus Rating
Spruce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.67, Spruce Biosciences has a forecasted upside of 222.1% from its current price of $2.38.
Amount of Analyst Coverage
Spruce Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.07% of the outstanding shares of Spruce Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Spruce Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Spruce Biosciences has recently decreased by 13.97%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Spruce Biosciences does not currently pay a dividend.
Dividend Growth
Spruce Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SPRB.

0.6

News and Social Media Coverage

MarketBeat Follows
1 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Spruce Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Spruce Biosciences is held by insiders.
Percentage Held by Institutions
78.58% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Spruce Biosciences are expected to decrease in the coming year, from ($1.40) to ($1.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Spruce Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Spruce Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Spruce Biosciences has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Spruce Biosciences (NASDAQ:SPRB) Stock

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

SPRB Price History

30 days | 90 days | 365 days | Advanced Chart

SPRB Stock News Headlines

September 15, 2023 | americanbankingnews.com

Spruce Biosciences' (SPRB) "Outperform" Rating Reiterated at Royal Bank of Canada

September 15, 2023 | americanbankingnews.com

Spruce Biosciences' (SPRB) "Buy" Rating Reaffirmed at HC Wainwright

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

September 13, 2023 | markets.businessinsider.com

Spruce Biosciences (SPRB) Gets a Buy from H.C. Wainwright

September 12, 2023 | markets.businessinsider.com

JMP Securities Sticks to Their Buy Rating for Spruce Biosciences (SPRB)

September 8, 2023 | msn.com

SVB Leerink Upgrades Spruce Biosciences (SPRB)

September 8, 2023 | markets.businessinsider.com

Analyst Ratings for Spruce Biosciences

August 28, 2023 | finance.yahoo.com

Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

August 18, 2023 | msn.com

HC Wainwright & Co. Reiterates Spruce Biosciences (SPRB) Buy Recommendation

August 18, 2023 | msn.com

Oppenheimer Maintains Spruce Biosciences (SPRB) Outperform Recommendation

August 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Spruce Biosciences (SPRB) and Alpha Tau Medical Ltd (DRTS)

August 16, 2023 | msn.com

JMP Securities Maintains Spruce Biosciences (SPRB) Outperform Recommendation

August 16, 2023 | markets.businessinsider.com

Expert Ratings for Spruce Biosciences

August 15, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

August 14, 2023 | finance.yahoo.com

Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

June 13, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Spruce Biosciences (SPRB), Vaccitech Plc (VACC)

June 12, 2023 | finance.yahoo.com

Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)

May 25, 2023 | finance.yahoo.com

Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors

May 24, 2023 | finance.yahoo.com

Spruce Biosciences to Participate in the Jefferies Healthcare Conference

May 23, 2023 | msn.com

Oppenheimer Reiterates Spruce Biosciences (SPRB) Outperform Recommendation

May 22, 2023 | finance.yahoo.com

Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES Gala

May 17, 2023 | msn.com

RBC Capital Reiterates Spruce Biosciences (SPRB) Outperform Recommendation

May 16, 2023 | msn.com

JMP Securities Reiterates Spruce Biosciences (SPRB) Market Outperform Recommendation

May 16, 2023 | msn.com

Credit Suisse Reiterates Spruce Biosciences (SPRB) Outperform Recommendation

May 16, 2023 | markets.businessinsider.com

Analyst Expectations for Spruce Biosciences's Future

May 16, 2023 | finance.yahoo.com

Investors in Spruce Biosciences (NASDAQ:SPRB) have seen decent returns of 63% over the past year

See More Headlines

Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SPRB Company Calendar

Last Earnings: 8/14/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SPRB
CUSIP: N/A
CIK: 1683553
Web: www.sprucebiosciences.com
Phone: 415-655-4168
Fax: N/A
Employees: 32
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.67
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +222.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,180,000.00
Net Margins: N/A
Pretax Margin: -1,166.41%
Return on Equity: -54.80%
Return on Assets: -43.19%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 5.46
Quick Ratio: 5.46

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.90 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 40,710,000
Free Float: 38,309,000
Market Cap: $96.89 million
Optionable: Not Optionable
Beta: 2.13

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Michael G. Grey (Age 70)
Exec. Chairman
Comp: $70k

Dr. Javier Szwarcberg M.D. (Age 53)
M.P.H., CEO & Director
Comp: $693.9k

Mr. Samir M. Gharib CPA (Age 41)
CPA, M.B.A., Pres & CFO
Comp: $536.13k

Dr. Ralph William Charlton III (Age 53)
M.D., Chief Medical Officer
Comp: $436.38k

Ms. P. J. Ramtin
Sr. VP of Bus. Operations

Ms. Heidi Petersen M.P.H.
Sr. VP of Regulatory & Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SPRB Stock - Frequently Asked Questions

Should I buy or sell Spruce Biosciences stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRB shares.
View SPRB analyst ratings or view top-rated stocks.
What is Spruce Biosciences' stock price forecast for 2023?: 6 Wall Street analysts have issued 12 month price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 222.1% from the stock's current price.
View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts.
How have SPRB shares performed in 2023?: Spruce Biosciences' stock was trading at $1.0974 at the beginning of the year. Since then, SPRB shares have increased by 116.9% and is now trading at $2.38.
View the best growth stocks for 2023 here.
When is Spruce Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SPRB earnings forecast.
How were Spruce Biosciences' earnings last quarter?: Spruce Biosciences, Inc. (NASDAQ:SPRB) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. The business earned $2.17 million during the quarter, compared to analyst estimates of $2.45 million.
When did Spruce Biosciences IPO?: (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

What is Spruce Biosciences' stock symbol?: Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB."
Who are Spruce Biosciences' major shareholders?: Spruce Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Worth Venture Partners LLC (0.70%), BlackRock Inc. (0.66%), Renaissance Technologies LLC (0.60%), Geode Capital Management LLC (0.55%), Citadel Advisors LLC (0.18%) and State Street Corp (0.15%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest.
View institutional ownership trends.
How do I buy shares of Spruce Biosciences?: Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Spruce Biosciences' stock price today?: One share of SPRB stock can currently be purchased for approximately $2.38.
How much money does Spruce Biosciences make?: Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $96.89 million. The company earns $-46,180,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.
How can I contact Spruce Biosciences?: The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com.

This page (NASDAQ:SPRB) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial